Annual EBIT
$170.36 M
+$260.11 M+289.82%
31 December 2023
Summary:
Amneal Pharmaceuticals annual earnings before interest & taxes is currently $170.36 million, with the most recent change of +$260.11 million (+289.82%) on 31 December 2023. During the last 3 years, it has risen by +$60.14 million (+54.57%). AMRX annual EBIT is now -36.93% below its all-time high of $401.10 million.AMRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$80.93 M
-$5.19 M-6.03%
30 September 2024
Summary:
Amneal Pharmaceuticals quarterly earnings before interest & taxes is currently $80.93 million, with the most recent change of -$5.19 million (-6.03%) on 30 September 2024. Over the past year, it has increased by +$7.07 million (+9.57%). AMRX quarterly EBIT is now -6.03% below its all-time high of $86.12 million, reached on 30 June 2024.AMRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$133.33 M
+$7.07 M+5.60%
30 September 2024
Summary:
Amneal Pharmaceuticals TTM earnings before interest & taxes is currently $133.33 million, with the most recent change of +$7.07 million (+5.60%) on 30 September 2024. Over the past year, it has dropped by -$100.32 million (-42.94%). AMRX TTM EBIT is now -48.33% below its all-time high of $258.03 million, reached on 31 March 2018.AMRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AMRX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +289.8% | +9.6% | -42.9% |
| 3 y3 years | +54.6% | +150.1% | -25.6% |
| 5 y5 years | +388.0% | +18.2% | +2446.9% |
AMRX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +289.8% | -6.0% | +141.1% | -42.9% | +207.8% |
| 5 y | 5 years | at high | +289.8% | -6.0% | +141.1% | -42.9% | +207.8% |
| alltime | all time | -36.9% | +289.8% | -6.0% | +135.8% | -48.3% | +160.0% |
Amneal Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $80.93 M(-6.0%) | $133.33 M(+5.6%) |
| June 2024 | - | $86.12 M(-977.1%) | $126.26 M(+4.6%) |
| Mar 2024 | - | -$9.82 M(-58.9%) | $120.65 M(-29.2%) |
| Dec 2023 | $170.36 M(-289.8%) | -$23.91 M(-132.4%) | $170.36 M(-27.1%) |
| Sept 2023 | - | $73.87 M(-8.3%) | $233.65 M(+14.3%) |
| June 2023 | - | $80.52 M(+101.9%) | $204.35 M(-378.9%) |
| Mar 2023 | - | $39.89 M(+1.3%) | -$73.28 M(-18.4%) |
| Dec 2022 | -$89.75 M(-153.5%) | $39.37 M(-11.7%) | -$89.75 M(-19.5%) |
| Sept 2022 | - | $44.57 M(-122.6%) | -$111.48 M(-9.9%) |
| June 2022 | - | -$197.11 M(-941.8%) | -$123.70 M(-186.9%) |
| Mar 2022 | - | $23.41 M(+32.7%) | $142.32 M(-15.1%) |
| Dec 2021 | $167.69 M(+52.1%) | $17.64 M(-45.5%) | $167.69 M(-6.4%) |
| Sept 2021 | - | $32.36 M(-53.0%) | $179.11 M(+12.1%) |
| June 2021 | - | $68.91 M(+41.2%) | $159.76 M(+51.1%) |
| Mar 2021 | - | $48.79 M(+67.9%) | $105.76 M(-4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $110.22 M(-311.8%) | $29.06 M(+123.4%) | $110.22 M(+75.3%) |
| Sept 2020 | - | $13.01 M(-12.8%) | $62.88 M(-46.9%) |
| June 2020 | - | $14.91 M(-72.0%) | $118.36 M(+29.9%) |
| Mar 2020 | - | $53.24 M(-391.2%) | $91.11 M(-275.1%) |
| Dec 2019 | -$52.04 M(-12.0%) | -$18.28 M(-126.7%) | -$52.04 M(+816.0%) |
| Sept 2019 | - | $68.48 M(-654.9%) | -$5.68 M(-33.7%) |
| June 2019 | - | -$12.34 M(-86.3%) | -$8.57 M(-96.1%) |
| Mar 2019 | - | -$89.90 M(-420.2%) | -$222.12 M(+275.5%) |
| Dec 2018 | -$59.15 M(-124.4%) | $28.07 M(-57.2%) | -$59.15 M(+1038.8%) |
| Sept 2018 | - | $65.59 M(-129.0%) | -$5.19 M(-79.4%) |
| June 2018 | - | -$225.88 M(-409.1%) | -$25.18 M(-109.8%) |
| Mar 2018 | - | $73.07 M(-10.9%) | $258.03 M(+39.5%) |
| Dec 2017 | $242.38 M(-10.3%) | $82.03 M(+79.9%) | $184.96 M(+79.7%) |
| Sept 2017 | - | $45.60 M(-20.5%) | $102.93 M(+79.5%) |
| June 2017 | - | $57.33 M | $57.33 M |
| Dec 2016 | $270.10 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual EBIT year-on-year change?
- What is Amneal Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly EBIT year-on-year change?
- What is Amneal Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM EBIT year-on-year change?
What is Amneal Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of AMRX is $170.36 M
What is the all time high annual EBIT for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual earnings before interest & taxes is $401.10 M
What is Amneal Pharmaceuticals annual EBIT year-on-year change?
Over the past year, AMRX annual earnings before interest & taxes has changed by +$260.11 M (+289.82%)
What is Amneal Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of AMRX is $80.93 M
What is the all time high quarterly EBIT for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly earnings before interest & taxes is $86.12 M
What is Amneal Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, AMRX quarterly earnings before interest & taxes has changed by +$7.07 M (+9.57%)
What is Amneal Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of AMRX is $133.33 M
What is the all time high TTM EBIT for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM earnings before interest & taxes is $258.03 M
What is Amneal Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, AMRX TTM earnings before interest & taxes has changed by -$100.32 M (-42.94%)